

# Comparisons of per cent-predicted peak oxygen uptake achieved on cardiopulmonary exercise testing: stratifying mortality risk by Wasserman, FRIEND, and Brazilian equations

**Fabricio Braga** <sup>1,2\*</sup>, **Mauricio Milani** <sup>3,4,5</sup>, **Gabriel Espinosa**<sup>1,6</sup>,  
**Juliana Goulart Prata Oliveira Milani**<sup>3,4</sup>, **Dominique Hansen**<sup>4,5,7</sup>,  
**Gerson Cipriano Junior**<sup>3,8</sup>, **Jonathan Myers**<sup>9</sup>, and **Ricardo Mourilhe-Rocha**<sup>2,10</sup>

<sup>1</sup>Laboratório de Performance Humana, Largo do Ibam, nº1 – 2º Floor, Humaitá, Rio de Janeiro, RJ, Brazil; <sup>2</sup>Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; <sup>3</sup>Health Sciences and Technologies Graduate Program, University of Brasília (UnB), Brasília, DF, Brazil; <sup>4</sup>Rehabilitation Research Center (REVAL), Faculty of Rehabilitation Sciences, Hasselt University, Hasselt, Belgium; <sup>5</sup>Department of Cardiology, Heart Centre Hasselt, Jessa Hospital, Hasselt, Belgium; <sup>6</sup>Universidade Federal Fluminense, Niterói, RJ, Brazil; <sup>7</sup>Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Hasselt, Belgium; <sup>8</sup>Graduate Program in Human Movement and Rehabilitation of Evangelical (PPGMHR), UniEVANGÉLICA, Anápolis, Brazil; <sup>9</sup>VA Palo Alto Health Care System and Stanford University, USA; and <sup>10</sup>Complexo Hospitalar Américas-Vitória and Samaritano Barra, Rio de Janeiro, RJ, Brazil

Received 7 March 2024; revised 7 June 2024; accepted 29 June 2024

Cardiorespiratory fitness (CRF) is an important prognostic marker,<sup>1–3</sup> and the direct measurement of peak oxygen uptake (VO<sub>2</sub>peak) by cardiopulmonary exercise testing (CPET) is considered the gold standard method.<sup>1</sup> Measured VO<sub>2</sub>peak is the most studied variable for risk assessment.<sup>4</sup> However, the VO<sub>2</sub>peak achieved compared to the percentage of age-predicted values (%VO<sub>2</sub>peak) is commonly employed in daily practice,<sup>5</sup> providing a more contextual understanding of individual CRF while considering variations due to age, sex, anthropometry, and nationality.<sup>6</sup>

The %VO<sub>2</sub>peak is calculated using specific equations, one of the oldest and most widely used being the Wasserman algorithm.<sup>7</sup> Previous studies have proposed various prediction equations for %VO<sub>2</sub>peak, each tailored to specific populations and exercise modalities.<sup>8</sup> Recently, the Fitness Registry and the Importance of Exercise National Database (FRIEND) registry developed a prediction equation for both treadmill and cycle ergometre.<sup>9</sup> In 2022, Milani *et al.*<sup>6</sup> conducted a pooled analysis of 26 661 assessments from three regions and generated a Brazilian prediction equation, representing a significant advancement given the diverse and region-specific characteristics of the population.

Regarding prognostic studies on %VO<sub>2</sub>peak, Myers *et al.*<sup>10</sup> compared the Wasserman and FRIEND registry equations in a heart failure database. The FRIEND registry equation demonstrated similar or slightly better performance than the Wasserman equation.<sup>11</sup> In another study involving the indirect estimation of VO<sub>2</sub>peak through a 1 km treadmill walking test, the FRIEND registry equation outperformed the Wasserman equation. Despite the availability of Brazilian reference values,<sup>6</sup> no prognostic studies have been conducted.

Hence, we aimed to assess the predictive capability for all-cause mortality in a Brazilian outpatient cohort using %VO<sub>2</sub>peak values derived from various prediction equations.

A cohort of individuals (aged 20–80, both sexes) underwent cycle ergometre CPET at a private centre from January 2018 to January 2023,

using an individualized ramp protocol. The %VO<sub>2</sub>peak was calculated using three prediction equations: Wasserman,<sup>7</sup> FRIEND registry,<sup>10</sup> and Brazilian.<sup>6</sup>

All-cause mortality was determined by cross-referencing national registry numbers with official Brazilian records. Survival status was verified between 1 and 30 April 2023. The study was approved by the Human Research Ethics Committee (CAAE: 35706720.4.0000.8093), and all patients provided informed consent.

Due to non-normal distribution, data were described using median and interquartile range (IQR). Receiver operating characteristic (ROC) curve analysis assessed the diagnostic performance of the equations. The Hanley–McNeil method calculated the standard error of area under the curve (AUC), and the DeLong approach compared differences in AUC—optimal %VO<sub>2</sub>peak thresholds balanced sensitivity and specificity for predicting mortality. Multivariate logistic regression models assessed the independent predictive ability of each equation for mortality, incorporating %VO<sub>2</sub>peak, age, and sex. A *P* < 0.05 was considered statistically significant. Data analysis was conducted using SPSS version 29.0 and MedCalc version 22.013.

A total of 2684 participants were included (62.4% males; mean age: 52.9 ± 14.5 years). The median follow-up was 451 days (IQR: 152, 575), and 31 deaths were recorded (1.2%). Non-survivors were significantly older than survivors [72 (IQR: 62, 76) vs. 52 (IQR: 42, 65) years; *P* < 0.001] and exhibited markedly reduced values in both absolute [1.20 (0.91, 1.52) vs. 1.98 (1.40, 2.72) L/min; *P* < 0.001] and relative VO<sub>2</sub>peak [15.7 (12.2, 17.3) vs. 25.6 (18.7, 34.3) mL/kg/min; *P* < 0.001]. The %VO<sub>2</sub>peak was consistently lower in non-survivors; however, heterogeneous values were observed (*Table 1*), consistent with the international variations described for CRF.<sup>6</sup>

In terms of prognosis, all three %VO<sub>2</sub>peak equations were significant predictors of all-cause mortality (*Figure 1A*), with AUC values ranging **AQB**

\* Corresponding author. Tel: +552125387730, Email: [fabricio.braga@lphoficial.com](mailto:fabricio.braga@lphoficial.com)

**Table 1** Clinical and physiological characteristics of study participants by vital status

Characteristics	Survivals (n = 2653)	Non-survivals (n = 31)	P-value
Age, years	52 (42, 65)	72 (62, 76)	<0.001
Male sex, n (%)	1652 (62.3%)	24 (77.4%)	0.083
Weight, kg	77.0 (66.7, 87.7)	71.5 (63.4, 87.3)	0.490
Height, cm	172 (165, 179)	169 (163, 176)	0.302
BMI, kg/m <sup>2</sup>	25.9 (23.4, 28.9)	25.8 (23.0, 30.5)	0.754
Comorbidities			
Hypertension, n (%)	861 (32.5%)	13 (41.9%)	0.263
Diabetes mellitus, n (%)	245 (9.2%)	8 (25.8%)	0.002
Dyslipidaemia, n (%)	906 (34.2%)	7 (22.6%)	0.176
Obesity, n (%)	491 (18.6%)	8 (25.8%)	0.306
Smoker (actual or former), n (%)	582 (21.9%)	16 (51.6%)	<0.001
Coronary artery disease, n (%)	329 (12.4%)	1 (3.2%)	0.122
Myocardial infarction, n (%)	105 (4%)	1 (3.2%)	0.835
Percutaneous angioplasty, n (%)	219 (8.7%)	1 (3.2%)	0.317
Coronary bypass surgery, n (%)	57 (2.1%)	0 (0%)	0.409
Heart failure, n (%)	114 (4.3%)	3 (9.7%)	0.145
Stroke, n (%)	21 (0.8%)	1 (3.2%)	0.135
Chronic obstructive pulmonary disease, n (%)	136 (5.1%)	6 (19.4%)	<0.001
Renal disease, n (%)	24 (0.9%)	1 (3.4%)	0.159
Cancer, n (%)	233 (8.8%)	15 (48.4%)	<0.001
Cardiorespiratory fitness			
VO <sub>2</sub> peak, L/min	1.98 (1.40, 2.72)	1.20 (0.91, 1.52)	<0.001
VO <sub>2</sub> peak, mL/kg/min	25.6 (18.7, 34.3)	15.7 (12.2, 17.3)	<0.001
%VO <sub>2</sub> peak			
Wasserman equation, <sup>7</sup> %	97 (80, 115)	67 (56, 84)	<0.001
FRIEND equation, <sup>9</sup> %	87 (72, 103)	63 (46, 77)	<0.001
Brazilian equation, <sup>6</sup> %	81 (65, 100)	56 (44, 75)	<0.001

Data expressed as median and IQR or absolute and relative frequency.

BMI, body mass index; VO<sub>2</sub>peak, peak oxygen uptake; %VO<sub>2</sub>peak, per cent-predicted peak oxygen uptake achieved.

from 0.753 (Brazilian) to 0.812 (Wasserman). The difference in AUC between the Wasserman and Brazilian equations was statistically significant ( $P = 0.018$ ). The FRIEND equation presented an intermediate AUC value (0.796), and it was not statistically different from either the Wasserman ( $P = 0.611$ ) or Brazilian ( $P = 0.329$ ) equations. The optimal cut-off points for %VO<sub>2</sub>peak were as follows:  $\leq 84\%$  for Wasserman (sensitivity: 80.7%; specificity: 69.4%),  $\leq 82\%$  for the FRIEND registry (sensitivity: 77.4%; specificity: 57.3%), and  $\leq 76\%$  for the Brazilian equation (sensitivity: 80.7%; specificity: 57.8%). The lower cut-off values for the Brazilian equation were most likely due to the ergometre specificity, as the equation was developed for a treadmill. This resulted in an overestimation of predicted VO<sub>2</sub>peak in our sample, as higher values are expected on a treadmill compared to a cycle ergometre.<sup>9</sup>


The three equations showed similar results in multivariate logistic regression models, with %VO<sub>2</sub>peak independently associated with mortality after controlling for age and sex, underscoring its significance in evaluating mortality risk.

This study initially explores the Brazilian equation's prognostic properties. Developed for treadmill assessments, it performed comparably

to the FRIEND equation and slightly inferior to the Wasserman equation. This highlights its potential clinical applicability. The AUC values for Wasserman and FRIEND were not statistically different, with similar cut-off values (84% vs. 82%), contrasting with previous studies showing slight superiority for the FRIEND equation.<sup>10,11</sup>

This study is limited by the low number of events. We did not include a Cox proportional hazards analysis due to potential overfitting and multicollinearity. Physical activity data were not available, and comorbidities, although listed in Table 1, were not included in the model, potentially affecting the prognostic value of VO<sub>2</sub>. Future studies with more events will address these issues.

In conclusion, our study provides insights into the prognostic utility of various VO<sub>2</sub>peak prediction equations. Each equation, adjusted for age and sex, is independently associated with all-cause mortality, underscoring %VO<sub>2</sub>peak's significance as a clinical predictor. The results highlight the challenges in establishing universal VO<sub>2</sub>peak reference values due to international heterogeneity, emphasizing the need for tailored approaches to assess CRF. Different %VO<sub>2</sub>peak cut-offs may be necessary to evaluate mortality risk based on the reference equation.



**B**

Multivariate Logistic Regression Analysis				
Prediction Equation	Variable	$\beta$	p value	OR (95% CI)
Wasserman <sup>7</sup>	Sex	-0.721	0.102	0.486 (0.205 to 1.153)
	Age	0.067	0.000	1.069 (1.034 to 1.106)
	%VO <sub>2</sub> peak	-0.048	0.000	0.953 (0.935 to 0.971)
FRIEND registry <sup>8</sup>	Sex	-0.452	0.315	0.636 (0.263 to 1.537)
	Age	0.073	0.000	1.075 (1.039 to 1.112)
	%VO <sub>2</sub> peak	-0.033	0.001	0.967 (0.949 to 0.986)
Brazilian <sup>6</sup>	Sex	-0.689	0.117	0.502 (0.212 to 1.188)
	Age	0.085	0.000	1.088 (1.050 to 1.128)
	%VO <sub>2</sub> peak	-0.042	0.000	0.959 (0.939 to 0.979)

**Figure 1** All-cause mortality prediction using Wasserman, FRIEND registry, and Brazilian peak oxygen uptake predictive equations. (A) Comparative analysis of receiver operating characteristic curves. (B) Multivariable logistic regression analysis. Statistical comparisons of the area under the curve: Wasserman vs. FRIEND:  $P = 0.611$ ; Wasserman vs. Brazilian:  $P = 0.018$ ; FRIEND vs. Brazilian:  $P = 0.329$ . AUC, area under the curve.

### Acknowledgements

None of the paper’s contents have been previously published. A partial analysis of the study will be presented at the ESC Preventive Cardiology Congress 2024.

### Author contribution

F.B. and M.M. contributed to the conception and design of the work. J.M., M.F., F.D., J.P., A.M., G.M., and B.F. contributed to data acquisition, analysis, or interpretation. F.B. and M.M. drafted the manuscript. J.G.P.O.M., D.H.,

G.C.J., J.M., and R.M.-R. critically revised the manuscript. All authors gave final approval and agreed to be accountable for all aspects of the work, ensuring integrity and accuracy.

## Funding

This study was funded in part by public research grants and scholarships from [Conselho Nacional de Desenvolvimento Científico e Tecnológico](#) [CNPq ([National Council of Scientific and Technological Development](#)), Brazil], [Coordenação de Aperfeiçoamento de Pessoal de Nível Superior](#) [CAPES ([Coordination for the Advancement of Higher Education Personnel](#)), Brazil], and [Special Research Fund](#) (BOF) from [Hasselt University](#)/Belgium (numbers BOF23DOCBL10 and BOF23KV10).

**Conflict of interest:** none declared.

## Data availability

The data supporting this study's findings are available from the corresponding author, [F.B.] upon reasonable request.

## References

- Ross R, Blair SN, Arena R, Church TS, Després J-P, Franklin BA, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. *Circulation* 2016;**134**:e653–e699.
- Laukkanen JA, Zaccardi F, Khan H, Kurl S, SY J, Rauramaa R. Long-term change in cardiorespiratory fitness and all-cause mortality: a population-based follow-up study. *Mayo Clin Proc* 2016;**91**:1183–1188.
- Braga F, Milani M, Fachetti A, Espinosa G, Moraes G, Milani JGPO, et al. Peak oxygen uptake after the 80s as a survival predictor. *Eur Geriatr Med* 2024.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–3726.
- Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Circulation* 2016;**133**:e694–e711.
- Milani M, Milani JGPO, Cipriano GFB, de Castro I, Cipriano Junior G. Reference standards for cardiorespiratory fitness in Brazil: a pooled analysis and overview of heterogeneity in national and international studies. *J Cardiopulm Rehabil Prev* 2022;**42**:366–372.
- Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. *Am Rev Respir Dis* 1984;**129**:S49–S55.
- Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N. Normal standards for an incremental progressive cycle ergometer test. *Am Rev Respir Dis* 1985;**131**:700–708.
- de Souza e Silva CG, Kaminsky LA, Arena R, Christle JW, Araújo CGS, Lima RM, et al. A reference equation for maximal aerobic power for treadmill and cycle ergometer exercise testing: analysis from the FRIEND registry. *Eur J Prev Cardiol* 2018;**25**:742–750.
- Myers J, Souza E, de Silva CG, Arena R, Kaminsky L, Christle JW, et al. Comparison of the FRIEND and Wasserman-Hansen equations in predicting outcomes in heart failure. *J Am Heart Assoc* 2021;**10**:e021246.
- Chiaranda G, Myers J, Arena R, Kaminsky L, Sassone B, Pasanisi G, et al. Prognostic comparison of the FRIEND and Wasserman/Hansen peak VO<sub>2</sub> equations applied to a sub-maximal walking test in outpatients with cardiovascular disease. *Eur J Prev Cardiol* 2021;**28**:287–292.